Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma Reply

被引：0
|
作者：
Pectasides, Dimitrios [1 ]
Dafni, Urania [2 ]
Gogas, Helen [3 ]
机构：
[1] Univ Gen Hosp Attikon, Dept Internal Med Propaedeut 2, Oncol Sect, Athens, Greece
[2] Univ Athens, Sch Nursing, Lab Biostat, Athens, Greece
[3] Univ Athens, Sch Med, Dept Med 1, Laiko Hosp, GR-11527 Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 24期
关键词：
D O I：
10.1200/JCO.2009.23.5333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E71 / E71
页数：1
相关论文
共 50 条
  • [1] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E70 - E70
  • [2] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84
  • [3] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
    Agarwala, Sanjiv S.
    Gray, Robert J.
    Wong, Michael K. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
  • [4] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    [J]. CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [5] Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b
    Fluck, M
    Kamanabrou, D
    Lippold, A
    Reitz, M
    Atzpodien, J
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (03) : 280 - 289
  • [6] Acute rhabdomyolysis associated with administration of high-dose interferon alfa-2b for high-risk melanoma
    Ramirez, A. Vanegas
    Fischer, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 50 - 50
  • [7] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [8] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [9] Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
    Kilbridge, KL
    Cole, BF
    Kirkwood, JM
    Haluska, FG
    Atkins, MA
    Ruckdeschel, JC
    Sock, DE
    Nease, RF
    Weeks, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1311 - 1318
  • [10] Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
    Levesque, N.
    Mitchinson, K.
    Lawrie, D.
    Fedorak, L.
    MacDonald, D.
    Normand, C.
    Pouliot, J. F.
    [J]. CURRENT ONCOLOGY, 2008, 15 (01) : 36 - 41
12345